We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Recordati

News List

Recordati to acquire EUSA Pharma to expand rare disease products portfolio Pharmaceutical-Technology
December 06, 2021
Italian company Recordati has signed an agreement to acquire EUSA Pharma in a deal worth about $848.9m (€750m) to expand its rare disease products portfolio.
Recordati acquires rights to Signifor and osilodrostat from Novartis pharmaceutical-technology
July 17, 2019
Recordati has agreed to acquire the global rights to two of Novartis’ medicines, Signifor and osilodrostat, for the treatment of patients suffering from endocrine diseases.
CVC Capital revs up rare disease ambitions with $3.5B Recordati buyout fiercepharma
July 03, 2018
Recordati has finally sealed a sale. Private equity player CVC Capital Partners said (PDF) Friday it would drop €3.03 billion